| Kathryn Elizabeth Weber, CNM | |
|
1500 E Medical Center Dr, Ann Arbor, MI 48109-5000 | |
| (734) 936-4000 | |
| Not Available |
| Full Name | Kathryn Elizabeth Weber |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 1500 E Medical Center Dr, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609492925 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | CNM06447 (Michigan) | Secondary |
| 367A00000X | Advanced Practice Midwife | 4704329569 (Michigan) | Primary |
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619992351 PECOS PAC ID: 3779496856 Enrollment ID: O20040607001157 |
News Archive
Laboratory Corporation of America Holdings announced today the nationwide availability of a new FDA cleared risk stratification tool (ROMA, Risk of Ovarian Malignancy Algorithm) that combines the results for Fujirebio HE4, Abbott's ARCHITECT CA 125 II, and menopausal status into a numerical score that, along with clinical and radiological evaluation, can aid in evaluating whether a woman over the age of 18 who presents with an ovarian mass and for whom surgery is planned is at high or low likelihood of finding malignancy on surgery.
A new review paper by the researchers from Spain, published in the journal Cytokine & Growth Factor Reviews, demonstrates how changes in the levels of cytokines and other biomolecules are associated with the presence and more serious prognosis of coronavirus disease (COVID-19).
Sanofi announced today that the U.S. Food and Drug Administration approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of Q2 2015.
The proportion of children who used a prescribed controller drug to treat their asthma doubled from 29 percent in 1997-1998 to 58 percent in 2007-2008, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Publicity surrounding the implementation of patient decision support interventions (DESIs) traditionally focuses on two areas of improvement: helping patients make better decisions AND lowering health care spending.
› Verified 3 days ago
| Entity Name | Women's Healthcare Associates Of Oakland Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568653780 PECOS PAC ID: 1254355878 Enrollment ID: O20060123000600 |
News Archive
Laboratory Corporation of America Holdings announced today the nationwide availability of a new FDA cleared risk stratification tool (ROMA, Risk of Ovarian Malignancy Algorithm) that combines the results for Fujirebio HE4, Abbott's ARCHITECT CA 125 II, and menopausal status into a numerical score that, along with clinical and radiological evaluation, can aid in evaluating whether a woman over the age of 18 who presents with an ovarian mass and for whom surgery is planned is at high or low likelihood of finding malignancy on surgery.
A new review paper by the researchers from Spain, published in the journal Cytokine & Growth Factor Reviews, demonstrates how changes in the levels of cytokines and other biomolecules are associated with the presence and more serious prognosis of coronavirus disease (COVID-19).
Sanofi announced today that the U.S. Food and Drug Administration approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of Q2 2015.
The proportion of children who used a prescribed controller drug to treat their asthma doubled from 29 percent in 1997-1998 to 58 percent in 2007-2008, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Publicity surrounding the implementation of patient decision support interventions (DESIs) traditionally focuses on two areas of improvement: helping patients make better decisions AND lowering health care spending.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathryn Elizabeth Weber, CNM 3621 S State St, Ann Arbor, MI 48108-1633 Ph: (734) 647-5299 | Kathryn Elizabeth Weber, CNM 1500 E Medical Center Dr, Ann Arbor, MI 48109-5000 Ph: (734) 936-4000 |
News Archive
Laboratory Corporation of America Holdings announced today the nationwide availability of a new FDA cleared risk stratification tool (ROMA, Risk of Ovarian Malignancy Algorithm) that combines the results for Fujirebio HE4, Abbott's ARCHITECT CA 125 II, and menopausal status into a numerical score that, along with clinical and radiological evaluation, can aid in evaluating whether a woman over the age of 18 who presents with an ovarian mass and for whom surgery is planned is at high or low likelihood of finding malignancy on surgery.
A new review paper by the researchers from Spain, published in the journal Cytokine & Growth Factor Reviews, demonstrates how changes in the levels of cytokines and other biomolecules are associated with the presence and more serious prognosis of coronavirus disease (COVID-19).
Sanofi announced today that the U.S. Food and Drug Administration approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of Q2 2015.
The proportion of children who used a prescribed controller drug to treat their asthma doubled from 29 percent in 1997-1998 to 58 percent in 2007-2008, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Publicity surrounding the implementation of patient decision support interventions (DESIs) traditionally focuses on two areas of improvement: helping patients make better decisions AND lowering health care spending.
› Verified 3 days ago
Samantha Kay Sharpe, RN, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Melissa D Furlette-koski, Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 4200 Whitehall Dr Ste 350, Ann Arbor, MI 48105 Phone: 734-572-9600 Fax: 734-572-0616 | |
Jan Margaret Buchanan, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1500 East Medical Center Dr, Von Voigtlander Women's Hospital, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Mrs. Jenni Lynn Schulz, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 4200 Whitehall Dr Ste 350, Ann Arbor, MI 48105 Phone: 734-572-9600 Fax: 734-572-0616 | |
Kenyatta Herndon, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 4200 Whitehall Dr Ste 350, Ann Arbor, MI 48105 Phone: 734-572-9600 Fax: 734-572-0616 | |
Jennifer Lynn Kelley, RN CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 4200 Whitehall Dr Ste 350, Ann Arbor, MI 48105 Phone: 734-572-9600 Fax: 734-572-0616 | |
Jennifer N Baughman, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1500 East Medical Center Dr, Von Voigtlander Women's Hospital, Ann Arbor, MI 48109 Phone: 734-936-4000 |